☆ 4.2 Article

Decreased serum glicentin concentration in patients with severe and morbid obesity

ANNALS OF CLINICAL BIOCHEMISTRY (2018)

Journal

ANNALS OF CLINICAL BIOCHEMISTRY

Volume 55, Issue 2, Pages 198-204

Publisher

SAGE PUBLICATIONS INC

DOI: 10.1177/0004563217700172

Keywords

Glicentin; obesity; proglucagon-derived peptides; metabolic changes

Funding

Universite 'Cote d'Azur
University Hospital of Nice

Ask authors/readers for more resources

Protocol

Community support

Reagent

Community support

Abstract

Background Proglucagon-derived hormones represent a family of peptides mainly produced in the pancreas and the intestine. While several proglucagon-derived peptides play key roles in metabolic diseases, little is known about glicentin. The aim of the present study was to investigate serum glicentin concentrations in individuals with adult obesity and to study its potential link with various metabolic parameters. Methods Fifty-two individuals with normal body mass index (BMI<25kg/m(2)) and 39 patients with severe or morbid obesity (BMI>35kg/m(2)) were prospectively included at the University Hospital of Nice between January 2014 and April 2016. Clinical data were recorded, and a fasting blood sample was collected to measure glicentin, glucose, insulin, C-peptide, total cholesterol, triglyceride, LDL and HDL-cholesterol. In addition, a homeostasis model assessment for insulin resistance (HOMA2-IR) was also calculated. Results Patients with severe and morbid obesity had significantly higher plasma glucose, together with higher serum concentrations of insulin, C-peptide, HOMA2-IR, triglyceride, LDL-cholesterol and lower serum concentrations of HDL-cholesterol compared with individuals with a normal body mass index. The obese patients displayed significantly lower fasting serum concentrations of glicentin compared with subjects with a normal body mass index (12pmol/L vs. 24pmol/L, P<0.0001). In the total population, fasting glicentin concentrations did not correlate with BMI, glycaemic parameters (glucose, insulin, C-peptide, HOMA-IR) or lipid parameters (total cholesterol, triglyceride, LDL and HDL-cholesterol). Conclusion To the best of our knowledge, this is the first study reporting serum glicentin concentrations in healthy lean and obese adult subjects. We found that fasting serum glicentin concentrations are decreased in patients with severe or morbid obesity suggesting the potential interest of this peptide in obesity and metabolic-related disorders.

Authors

I am an author on this paper

Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.2

Not enough ratings

Secondary Ratings

Novelty

Significance

Scientific rigor

Rate this paper

Circulating levels of proglucagon-derived peptides are differentially regulated by the glucagon-like peptide-1 agonist liraglutide and the centrally acting naltrexone/bupropion and can predict future weight loss and metabolic improvements: A 6-month long interventional study

Konstantinos Stefanakis, Alexander Kokkinos, Georgia Argyrakopoulou, Sofia K. Konstantinidou, Stamatia Simati, Matina Kouvari, Ajay Kumar, Bhanu Kalra, Melina Kumar, Nikolaos Bontozoglou, Konstantina Kyriakopoulou, Christos S. Mantzoros

Summary: The study investigated the changes in circulating levels of proglucagon-derived peptides (PGDPs) in individuals with overweight or obesity receiving liraglutide or naltrexone/bupropion treatment. Both medications improved body weight, composition, metabolism, and liver function. Liraglutide upregulated total glucagon-like peptide-1 (GLP-1) levels, while naltrexone/bupropion produced a weight-independent increase in proglucagon levels and decreases in GLP-2, glucagon, and the major proglucagon fragment. The changes in PGDP levels were associated with improvements in metabolism.

DIABETES OBESITY & METABOLISM (2023)